#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Facioscapulohumeral muscular dystrophy Liposarcoma recurrent Retinopathy proliferative Gaucher's disease type III Thromboangiitis obliterans Intracranial calcification Acute myeloid leukaemia Cardiac amyloidosis Oesophageal squamous cell carcinoma stage III Hereditary optic atrophy Angiosarcoma non-metastatic Leiomyosarcoma recurrent Mucopolysaccharidosis I Fontan procedure Insulinoma More trials…

    Learn about Rare Diseases

    Gaucher’s disease type III – Diagnostics Phenylketonuria – Treatment Glomerulonephritis membranous – Treatment Sarcoma – Treatment Burkitt’s lymphoma – Basic Information Uterine leiomyosarcoma – Treatment Familial amyotrophic lateral sclerosis – Life with Disease Leiomyosarcoma – Basic Information Mast cell activation syndrome – Life with Disease Sjogren’s syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Asp1570 Ab-1002 Rondaptivon Pegol His203-Crm197 Human Mesenchymal Stem Cells RO7288817 Magrolimab Lithium Carbonate Ciprofloxacin Hydrochloride Verapamil Ulipristal Acetate Nitrous Oxide Anhydrous Cidofovir Bt8009 Hct116-A Asciminib Hydrochloride Xylitol Cholic Acid Ilofotase Alfa Ambrisentan More therapies…

    Learn about Your Condition

    Erythema multiforme Neutropenia Cutibacterium acnes infection Methylmalonic acidaemia C3 glomerulopathy Hypertrophic cardiomyopathy Seizure Trigeminal neuralgia T-cell type acute leukaemia Post-traumatic headache Neurotrophic keratopathy Neuroblastoma Cervix carcinoma stage I Angiosarcoma recurrent Encephalitis Japanese B More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Duchenne muscular dystrophy gene carrier

  • Long‑Term Safety and Efficacy Study of ENTR‑601‑45 and ENTR‑601‑44 in Participants with Duchenne Muscular Dystrophy

    Recruiting

    2 1 1
    Belgium Italy The Netherlands Spain

  • Study of ENTR-601-45 Safety and Effectiveness in Patients with Duchenne Muscular Dystrophy Who Can Skip Exon 45

    Recruiting

    2 1 1
    Investigated Diseases:
    • Duchenne muscular dystrophy
    Investigated Drugs:
    • Sodium Chloride
    Belgium France Italy The Netherlands Poland Spain

  • Study of ENTR-601-44 in Children with Duchenne Muscular Dystrophy Who Are Eligible for Exon 44 Skipping Treatment

    Recruiting

    1 1 1
    Investigated Diseases:
    • Duchenne muscular dystrophy
    Investigated Drugs:
    • Sodium Chloride
    Belgium Italy Spain

  • Long-term Safety Study of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy Who Previously Received SRP-9001

    Recruiting

    3 1 1
    Investigated Diseases:
    • Duchenne muscular dystrophy
    Investigated Drugs:
    • Delandistrogene Moxeparvovec
    Belgium Germany Italy Spain

  • Study on the Safety and Effectiveness of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Duchenne muscular dystrophy
    Investigated Drugs:
    • Delandistrogene Moxeparvovec
    Belgium France Germany Italy Spain Sweden

  • Study on the Safety and Effects of Delandistrogene Moxeparvovec in Children Under 4 with Duchenne Muscular Dystrophy

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Delandistrogene Moxeparvovec
    Belgium France Germany Italy Spain
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!